Hepatic encephalopathy due to non-cirrhotic portal hypertension associated with non-alcoholic steatohepatitis and chronic hepatitis B: a Case Report. [PDF]
Li H +5 more
europepmc +1 more source
2. Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalchoholic Steatohepatitis (NASH)
S. Ohnishi, T. Saibara
openalex +2 more sources
Cuproptosis as a Potential Therapeutic Target for Steatotic Liver Disease. [PDF]
Pan Y, Luo C, Guo Q, Duan Q, Wu Z, Li Y.
europepmc +1 more source
Burden of liver cancer resulting from different etiologies in China from 1990 to 2021 and prediction to 2031. [PDF]
Zhang M +7 more
europepmc +1 more source
Roles of short-chain fatty acids in metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis. [PDF]
Zhang CY, Liu S, Sui YX, Yang M.
europepmc +1 more source
Metabolic-Associated Steatotic Liver Disease and FGF21 Dysregulation in Seipin-Deficient and <i>BSCL2</i>-Associated Celia's Encephalopathy Murine Models. [PDF]
Cobelo-Gómez S +9 more
europepmc +1 more source
NGM282: a step forward in the nonalcoholic steatohepatitis treatment landscape?
Luca Valenti, Valério Nobili
openalex +2 more sources

